Personalis, Inc. - Common Stock (PSNL)
Frequently Asked Questions About Personalis, Inc. - Common Stock (PSNL)
Does Personalis, Inc. offer international services?
Yes, Personalis, Inc. offers international services and collaborates with clients and partners around the globe. The company's advanced genomic solutions are utilized by research and healthcare institutions outside the United States, making it a key player in the global personalized medicine landscape.
Has Personalis, Inc. received any awards or recognitions?
Yes, Personalis, Inc. has received multiple awards and recognitions for its innovations in genomic medicine and contributions to personalized healthcare. These accolades highlight the company’s leadership in advancing next-generation sequencing technologies and its commitment to improving patient outcomes through precision medicine.
How can customers get started with Personalis, Inc.'s services?
Customers interested in utilizing Personalis, Inc.'s services can begin by reaching out to the company through its website or contacting their sales team. The process typically involves discussing specific needs and objectives, selecting appropriate services, and setting up a collaborative framework for genomic profiling and analysis.
How does Personalis, Inc. ensure data security?
Personalis, Inc. ensures data security through a combination of robust cybersecurity measures, compliance with regulatory standards such as HIPAA, and strict internal policies for data access and management. The company places a high priority on protecting patient information and maintaining the confidentiality of sensitive genomic data.
How does Personalis, Inc. stay competitive?
Personalis, Inc. stays competitive by continuously investing in research and development to enhance its genomic technology offerings, cultivating strategic partnerships, and maintaining a strong focus on customer needs and industry trends. By prioritizing innovation and adaptability, the company ensures it can meet the evolving demands of the precision medicine market.
Is Personalis, Inc. publicly traded?
Yes, Personalis, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol PSNL. The company went public through an initial public offering (IPO) in 2020, allowing it to raise capital to support its growth and innovation strategies in genomic medicine.
What differentiates Personalis, Inc. from its competitors?
What differentiates Personalis, Inc. from its competitors is its integrated approach to genomic profiling and its proprietary technologies that allow for more comprehensive and accurate tumor analysis. The company focuses on delivering actionable insights that are tailored specifically for precision medicine in oncology, which enhances its value proposition to researchers and clinicians.
What does Personalis, Inc. do?
Personalis, Inc. is a molecular information company that specializes in next-generation sequencing (NGS) to provide genomic data analysis and insights, primarily focused on precision medicine. The company offers services that assist in the development of personalized therapies across a variety of diseases, including cancer, through comprehensive genomic testing. Their platform enables researchers and clinicians to gain a deeper understanding of the genetic profile of patients to enhance treatment efficacy.
What is the company's stance on sustainability?
Personalis, Inc. is committed to sustainability and ethical practices in its operations. The company recognizes the importance of minimizing its environmental impact and engages in initiatives that promote responsible resource use, waste reduction, and sustainable business practices while delivering high-quality genomic services.
What is the future outlook for Personalis, Inc.?
The future outlook for Personalis, Inc. is positive, as the demand for personalized medicine continues to grow alongside advancements in genomic technologies. The company is positioned to expand its market presence, enhance its service offerings, and leverage new collaborations in the oncology sector, thereby paving the way for innovative solutions in patient care.
What is the main technology used by Personalis, Inc.?
The main technology utilized by Personalis, Inc. is its next-generation sequencing (NGS) platform, which allows for the comprehensive analysis of genomic data. This technology helps in the identification of genetic variants, the assessment of tumor genomic profiles, and the understanding of disease mechanisms, ultimately contributing to personalized therapeutic strategies.
What is the role of bioinformatics in Personalis, Inc.'s services?
Bioinformatics plays a crucial role in Personalis, Inc.'s services by enabling the effective interpretation and analysis of complex genomic data. The company employs advanced bioinformatics tools and algorithms to convert raw sequencing information into actionable insights, allowing researchers and clinicians to make informed decisions regarding treatment options.
What is the vision of Personalis, Inc.?
The vision of Personalis, Inc. is to transform patient care through advanced genomic insights that enable personalized medicine. The company aims to empower healthcare providers with comprehensive genomic data that drives effective decision-making in treatment and accelerates the development of therapies tailored to individual patients.
What partnerships does Personalis, Inc. have?
Personalis, Inc. has formed strategic partnerships with a variety of academic institutions, pharmaceutical companies, and research organizations. These collaborations aim to advance cancer research, enhance therapeutic approaches, and facilitate access to cutting-edge genomic technologies, thereby fostering innovation in precision medicine.
What services does Personalis, Inc. provide?
Personalis, Inc. provides a range of services including whole genome sequencing, tumor profiling, and bioinformatics analyses. These services are designed to facilitate the understanding of a patient's genetic makeup, support biomarker discovery, and aid in the development of targeted therapies, particularly in oncology.
What types of cancer does Personalis, Inc. focus on?
Personalis, Inc. focuses on various types of cancer, with an emphasis on solid tumors. Their genomic profiling services and research efforts primarily target prevalent cancers such as breast, lung, colon, and melanoma, providing clinicians with critical information for personalized treatment plans.
When was Personalis, Inc. founded?
Personalis, Inc. was founded in 2011. Since its inception, the company has focused on leveraging advanced genomic technologies to provide solutions for cancer research and precision medicine, with a mission to personalize patient care through data-driven insights.
Where is Personalis, Inc. headquartered?
Personalis, Inc. is headquartered in Menlo Park, California. This location is part of Silicon Valley, a hub for biotechnology and information technology, allowing the company to benefit from a vibrant ecosystem of innovation, talent, and collaboration in the life sciences sector.
Who are the target customers of Personalis, Inc.?
Personalis, Inc. primarily targets biopharmaceutical companies, academic institutions, and healthcare providers. These customers seek high-quality genomic data and insights to support drug discovery, clinical trials, and tailored treatment plans for patients, especially in the field of oncology.
What is the current price of Personalis, Inc. - Common Stock?
The current price of Personalis, Inc. - Common Stock is 3.125
When was Personalis, Inc. - Common Stock last traded?
The last trade of Personalis, Inc. - Common Stock was at 2:54 pm EDT on April 4th, 2025
What is the market capitalization of Personalis, Inc. - Common Stock?
The market capitalization of Personalis, Inc. - Common Stock is 151.62M
How many shares of Personalis, Inc. - Common Stock are outstanding?
Personalis, Inc. - Common Stock has 48.52M shares outstanding.